CollaGenex Pharmaceuticals Inc., of Newtown, Pa., appointed Klaus Theobald as senior vide president and chief medical officer.
Conforma Therapeutics Corp., of San Diego, elected Robert Bechard, Maxine Gowen, David Thompson and Eckard Weber to the company's board.
CoTherix Inc., of Belmont, Calif., appointed Thomas Feldman as chief commercial officer and Curtis Ruegg as senior vice president of technical operations.
Crucell NV, of Leiden, the Netherlands, appointed Ronald Brus president and CEO, replacing Dinko Valerio. Brus also will assume the role of chairman of the management board.
Dendreon Corp., of Seattle, added Andrew Scherer as vice president of manufacturing.
DOV Pharmaceutical Inc., of Hackensack, N.J., added Theresa Bischoff to its board.
Genentech Inc., of South San Francisco, appointed Hal Barron senior vice president of development, Varun Nanda vice president of sales and marketing and Patrick Yang vice president of South San Francisco manufacturing and engineering.
Genitope Corp., of Redwood City, Calif., said Dan Denney, the company's chairman and CEO, will act as chief financial officer.
Genomics Collaborative Inc., of Cambridge, Mass., appointed Rick Episcopo president and John Boyce senior director of business development. Also, Kevin Krenitsky now is senior vice president of business development.
Gentra Systems, of Minneapolis, appointed Daniel Bowman executive vice president of commercial operations.
Hypnion Inc., of Worcester, Mass., appointed Robert Poole chief medical officer.
ICOS Corp., of Bothell, Wash., said Jack Schuler was appointed to the company's board.
ID Biomedical, of Vancouver, British Columbia, appointed Mustapha Bakali chief operating officer.
Idun Pharmaceuticals Inc., of San Diego, appointed Jennifer Giottonini vice president of corporate development.
ILEX Oncology Inc., of San Antonio, promoted Steven Weitman to senior vice president and chief medical officer and Terry Murdock to senior vice president, clinical operations.
ImClone Systems Inc., of New York, appointed William Crouse and David Sidransky to the company's board.
Immusol, of San Diego, appointed Nicholas Paoni vice president of therapeutics. It also appointed Clark Springgate vice president of clinical and regulatory.
Integrated BioPharma Inc., of Hillside, N.J., elected Robert Kay, Glenn Chang and Zarko Kraljevic to its board.
InterMune Inc., of Brisbane, Calif., appointed Michael Smith to the company's board.
IR BioSciences Holdings Inc., of Scottsdale, Ariz., added Akihiro Shimosaka to its scientific advisory board for its wholly owned subsidiary, ImmuneRegen BioSciences Inc.